Free Webex Call
The Global Neoantigen Cancer Vaccine Market is projected to grow with a CAGR of 54.18% during the forecast period and is expected to reach USD 1754.44 million by 2026. The key factors responsible for the growth of neoantigen cancer vaccine market include rapid innovations in technology as well as infrastructural developments in healthcare sector. Additionally, growing investments by the governing bodies and healthcare providers is another major factor that is anticipated to boost the growth of neoantigen cancer vaccine market across the globe in the coming years.Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Global Neoantigen Cancer Vaccine Market is segmented based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, region, and company. Based on route of administration, the market can be segmented into intravenous, intramuscular, transdermal and others. Out of which, the intravenous segment is expected to dominate the market through 2026 and intramuscular is anticipated to be the fastest growing segment in the forecast period. This growth can be accredited to quick response as well as to the fact that drug dosage can be controlled easily. Along with that, intramuscular injections can be used rather than intravenous because some drugs cause irritation to veins when injected intravenously. This is expected to result in high growth of intramuscular route of administration segment in the coming years.
The application segment is further segregated into lung, melanoma, gastrointestinal, brain cancer, and others. The lung cancer segment is going to dominate the market in the forecast period as the neoantigen based immunotherapy of OSE Immunotherapeutic, which is in development for the Tedopi (OSE2101) neoantigen cancer vaccine is expected to launch in 2022. Tedopi (OSE2101), is used in the treatment of HLA-A2+ Lung cancer (NSCLC) patients. Currently, the vaccine is in phase III stage of clinical development.
Regionally, Asia Pacific neoantigen cancer vaccine market is expected to be the leading region over the forecast period due to the rising prevalence and incidence of cancer cases including lung cancer, melanoma, gastrointestinal, pancreatic cancer and other solid tumor indications.
Major players operating in the Global Neoantigen Cancer Vaccine Market include OSE Immunotherapeutics SA, Gritstone bio, Inc., BioNTech SE, F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co., Inc., Moderna Inc., Avidea Technologies, Inc., Eli Lilly and Company, Vaccibody AS, Agenus Inc., Novogene Co., Ltd., ZIOPHARM Oncology Inc., ISA Pharmaceuticals B.V., BrightPath Biotherapeutics Co., Ltd., Vaximm AG, Medigene AG, Genocea Biosciences Inc., Advaxis, Inc., Nouscom AG, among others are the leading players operating in the Global Neoantigen Cancer Vaccine Market. The companies operating in the market across the globe are focusing more towards expanding their share in the market.
Years considered for this report:
- Base Year: 2020
- Estimated Year: 2022
- Forecast Period: 2023-2026
Objective of the Study:
- To analyze and forecast the market size of the Global Neoantigen Cancer Vaccine Market.
- To classify and forecast the Global Neoantigen Cancer Vaccine Market based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, company and regional distribution from 2021 to 2026 and growth rate until 2026.
- To identify drivers and challenges for the Global Neoantigen Cancer Vaccine Market.
- To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the Global Neoantigen Cancer Vaccine Market.
- To conduct pricing analysis for the Global Neoantigen Cancer Vaccine Market.
- To identify and analyze the profile of leading players operating in the Global Neoantigen Cancer Vaccine Market.
The publisher performed both primary as well as exhaustive secondary research for this study. Initially, the publisher sourced a list of manufacturers across the globe. Subsequently, the publisher conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the manufacturers which could not be identified due to the limitations of secondary research. The publisher analyzed the new products, distribution channels and presence of all major players across the globe.
The publisher calculated the market size of the Global Neoantigen Cancer Vaccine Market by using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The publisher sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.
Key Target Audience:
- Neoantigen cancer vaccine manufacturers and other stakeholders
- Government bodies such as regulating authorities and policy makers
- Organizations, forums and alliances related to neoantigen cancer vaccine
- Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, partners, end-users, etc., besides allowing them in strategizing investments and capitalizing on the market opportunities.
Report Scope:
In this report, the Global Neoantigen Cancer Vaccine Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Global Neoantigen Cancer Vaccine Market, By Product:
- Personalized neo-antigen vaccine
- Off-the shelf neoantigen vaccine
Global Neoantigen Cancer Vaccine Market, By Neoantigen Type:
- Synthetic Long Peptide
- Nucleic acid
- Dendritic cell
- Tumor cell
Global Neoantigen Cancer Vaccine Market, By Route of Administration:
- Intravenous
- Intramuscular
- Transdermal
- Others
Global Neoantigen Cancer Vaccine Market, By Cell:
- Autologous
- Allogenic
Global Neoantigen Cancer Vaccine Market, By Technology:
- RNA Sequencing
- Whole Genome Sequencing
- HLA Typing
Global Neoantigen Cancer Vaccine Market, By Delivery Mechanism:
- Liposomes
- Virosomes
- Gene gun
- Electroporation
- Others
Global Neoantigen Cancer Vaccine Market, By Application:
- Lung
- Melanoma
- Gastrointestinal
- Brain cancer
- Others
Global Neoantigen Cancer Vaccine Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Singapore
- South America
- Brazil
- Argentina
- Colombia
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Neoantigen Cancer Vaccine Market.
Available Customizations:
With the given market data, the publisher offers customizations according to a company’s specific needs.
Table of Contents
1. Product Overview2. Research Methodology
3. Clinical Trial Analysis
4. Executive Summary
5. Global Neoantigen Cancer Vaccine Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value & Volume
5.2. Market Share & Forecast
5.2.1. By Product (Personalized Neo-antigen Vaccine, Off-the Shelf Neoantigen Vaccine)
5.2.2. By Neoantigen Type (Synthetic Long Peptide (SLP), Dendritic Cell, Nucleic Acid, Tumor Cell)
5.2.3. By Route of Administration (Intravenous, Intramuscular, Transdermal, Others)
5.2.4. By Cell (Autologous, Allogenic)
5.2.5. By Technology (RNA Sequencing, Whole Genome Sequencing, HLA Typing)
5.2.6. By Delivery Mechanism (Liposomes, Virosomes, Electroporation, Gene gun and Others)
5.2.7. By Application (Lung, Melanoma, Gastrointestinal, Brain cancer, and Others)
5.2.8. By Company (2023)
5.2.9. By Region
5.3. Product Market Map
6. North America Neoantigen Cancer Vaccine Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value & Volume
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Neoantigen Type
6.2.3. By Route of Administration
6.2.4. By Cell
6.2.5. By Technology
6.2.6. By Application
6.2.7. By Country
6.3. Product Market Map
6.4. North America: Country Analysis
6.4.1. United States Neoantigen Cancer Vaccine Market Outlook
6.4.1.1. Market Size & Forecast
6.4.1.1.1. By Value
6.4.1.2. Market Share & Forecast
6.4.1.2.1. By Product
6.4.1.2.2. By Neoantigen Type
6.4.1.2.3. By Route of Administration
6.4.1.2.4. By Cell
6.4.1.2.5. By Technology
6.4.1.2.6. By Application
6.4.2. Canada Neoantigen Cancer Vaccine Market Outlook
6.4.2.1. Market Size & Forecast
6.4.2.1.1. By Value
6.4.2.2. Market Share & Forecast
6.4.2.2.1. By Product
6.4.2.2.2. By Neoantigen Type
6.4.2.2.3. By Route of Administration
6.4.2.2.4. By Cell
6.4.2.2.5. By Technology
6.4.2.2.6. By Application
6.4.3. Mexico Neoantigen Cancer Vaccine Market Outlook
6.4.3.1. Market Size & Forecast
6.4.3.1.1. By Value
6.4.3.2. Market Share & Forecast
6.4.3.2.1. By Product
6.4.3.2.2. By Neoantigen Type
6.4.3.2.3. By Route of Administration
6.4.3.2.4. By Cell
6.4.3.2.5. By Technology
6.4.3.2.6. By Application
7. Europe Neoantigen Cancer Vaccine Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Neoantigen Type
7.2.3. By Route of Administration
7.2.4. By Cell
7.2.5. By Technology
7.2.6. By Application
7.2.7. By Country
7.3. Product Market Map
7.4. Europe: Country Analysis
7.4.1. Germany Neoantigen Cancer Vaccine Market Outlook
7.4.1.1. Market Size & Forecast
7.4.1.1.1. By Value
7.4.1.2. Market Share & Forecast
7.4.1.2.1. By Product
7.4.1.2.2. By Neoantigen Type
7.4.1.2.3. By Route of Administration
7.4.1.2.4. By Cell
7.4.1.2.5. By Technology
7.4.1.2.6. By Application
7.4.2. France Neoantigen Cancer Vaccine Market Outlook
7.4.2.1. Market Size & Forecast
7.4.2.1.1. By Value
7.4.2.2. Market Share & Forecast
7.4.2.2.1. By Product
7.4.2.2.2. By Neoantigen Type
7.4.2.2.3. By Route of Administration
7.4.2.2.4. By Cell
7.4.2.2.5. By Technology
7.4.2.2.6. By Application
7.4.3. United Kingdom Neoantigen Cancer Vaccine Market Outlook
7.4.3.1. Market Size & Forecast
7.4.3.1.1. By Value
7.4.3.2. Market Share & Forecast
7.4.3.2.1. By Product
7.4.3.2.2. By Neoantigen Type
7.4.3.2.3. By Route of Administration
7.4.3.2.4. By Cell
7.4.3.2.5. By Technology
7.4.3.2.6. By Application
7.4.4. Italy Neoantigen Cancer Vaccine Market Outlook
7.4.4.1. Market Size & Forecast
7.4.4.1.1. By Value
7.4.4.2. Market Share & Forecast
7.4.4.2.1. By Product
7.4.4.2.2. By Neoantigen Type
7.4.4.2.3. By Route of Administration
7.4.4.2.4. By Cell
7.4.4.2.5. By Technology
7.4.4.2.6. By Application
7.4.5. Spain Neoantigen Cancer Vaccine Market Outlook
7.4.5.1. Market Size & Forecast
7.4.5.1.1. By Value
7.4.5.2. Market Share & Forecast
7.4.5.2.1. By Product
7.4.5.2.2. By Neoantigen Type
7.4.5.2.3. By Route of Administration
7.4.5.2.4. By Cell
7.4.5.2.5. By Technology
7.4.5.2.6. By Application
8. Asia-Pacific Neoantigen Cancer Vaccine Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value & Volume
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Neoantigen Type
8.2.3. By Route of Administration
8.2.4. By Cell
8.2.5. By Technology
8.2.6. By Application
8.2.7. By Country
8.3. Product Market Map
8.4. Asia-Pacific: Country Analysis
8.4.1. China Neoantigen Cancer Vaccine Market Outlook
8.4.1.1. Market Size & Forecast
8.4.1.1.1. By Value
8.4.1.2. Market Share & Forecast
8.4.1.2.1. By Product
8.4.1.2.2. By Neoantigen Type
8.4.1.2.3. By Route of Administration
8.4.1.2.4. By Cell
8.4.1.2.5. By Technology
8.4.1.2.6. By Application
8.4.2. India Neoantigen Cancer Vaccine Market Outlook
8.4.2.1. Market Size & Forecast
8.4.2.1.1. By Value
8.4.2.2. Market Share & Forecast
8.4.2.2.1. By Product
8.4.2.2.2. By Neoantigen Type
8.4.2.2.3. By Route of Administration
8.4.2.2.4. By Cell
8.4.2.2.5. By Technology
8.4.2.2.6. By Application
8.4.3. Japan Neoantigen Cancer Vaccine Market Outlook
8.4.3.1. Market Size & Forecast
8.4.3.1.1. By Value
8.4.3.2. Market Share & Forecast
8.4.3.2.1. By Product
8.4.3.2.2. By Neoantigen Type
8.4.3.2.3. By Route of Administration
8.4.3.2.4. By Cell
8.4.3.2.5. By Technology
8.4.3.2.6. By Application
8.4.4. Australia Neoantigen Cancer Vaccine Market Outlook
8.4.4.1. Market Size & Forecast
8.4.4.1.1. By Value
8.4.4.2. Market Share & Forecast
8.4.4.2.1. By Product
8.4.4.2.2. By Neoantigen Type
8.4.4.2.3. By Route of Administration
8.4.4.2.4. By Cell
8.4.4.2.5. By Technology
8.4.4.2.6. By Application
8.4.5. South Korea Neoantigen Cancer Vaccine Market Outlook
8.4.5.1. Market Size & Forecast
8.4.5.1.1. By Value
8.4.5.2. Market Share & Forecast
8.4.5.2.1. By Product
8.4.5.2.2. By Neoantigen Type
8.4.5.2.3. By Route of Administration
8.4.5.2.4. By Cell
8.4.5.2.5. By Technology
8.4.5.2.6. By Application
8.4.6. Singapore Neoantigen Cancer Vaccine Market Outlook
8.4.6.1. Market Size & Forecast
8.4.6.1.1. By Value
8.4.6.2. Market Share & Forecast
8.4.6.2.1. By Product
8.4.6.2.2. By Neoantigen Type
8.4.6.2.3. By Route of Administration
8.4.6.2.4. By Cell
8.4.6.2.5. By Technology
8.4.6.2.6. By Application
9. South America Neoantigen Cancer Vaccine Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value & Volume
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Neoantigen Type
9.2.3. By Route of Administration
9.2.4. By Cell
9.2.5. By Technology
9.2.6. By Application
9.2.7. By Country
9.3. Product Market Map
9.4. South America: Country Analysis
9.4.1. Brazil Neoantigen Cancer Vaccine Market Outlook
9.4.1.1. Market Size & Forecast
9.4.1.1.1. By Value
9.4.1.2. Market Share & Forecast
9.4.1.2.1. By Product
9.4.1.2.2. By Neoantigen Type
9.4.1.2.3. By Route of Administration
9.4.1.2.4. By Cell
9.4.1.2.5. By Technology
9.4.1.2.6. By Application
9.4.2. Argentina Neoantigen Cancer Vaccine Market Outlook
9.4.2.1. Market Size & Forecast
9.4.2.1.1. By Value
9.4.2.2. Market Share & Forecast
9.4.2.2.1. By Product
9.4.2.2.2. By Neoantigen Type
9.4.2.2.3. By Route of Administration
9.4.2.2.4. By Cell
9.4.2.2.5. By Technology
9.4.2.2.6. By Application
9.4.3. Colombia Neoantigen Cancer Vaccine Market Outlook
9.4.3.1. Market Size & Forecast
9.4.3.1.1. By Value
9.4.3.2. Market Share & Forecast
9.4.3.2.1. By Product
9.4.3.2.2. By Neoantigen Type
9.4.3.2.3. By Route of Administration
9.4.3.2.4. By Cell
9.4.3.2.5. By Technology
9.4.3.2.6. By Application
10. Middle East and Africa Neoantigen Cancer Vaccine Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value & Volume
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Neoantigen Type
10.2.3. By Route of Administration
10.2.4. By Cell
10.2.5. By Technology
10.2.6. By Application
10.2.7. By Country
10.3. Product Market Map
10.4. MEA: Country Analysis
10.4.1. South Africa Neoantigen Cancer Vaccine Market Outlook
10.4.1.1. Market Size & Forecast
10.4.1.1.1. By Value
10.4.1.2. Market Share & Forecast
10.4.1.2.1. By Product
10.4.1.2.2. By Neoantigen Type
10.4.1.2.3. By Route of Administration
10.4.1.2.4. By Cell
10.4.1.2.5. By Technology
10.4.1.2.6. By Application
10.4.2. Saudi Arabia Neoantigen Cancer Vaccine Market Outlook
10.4.2.1. Market Size & Forecast
10.4.2.1.1. By Value
10.4.2.2. Market Share & Forecast
10.4.2.2.1. By Product
10.4.2.2.2. By Neoantigen Type
10.4.2.2.3. By Route of Administration
10.4.2.2.4. By Cell
10.4.2.2.5. By Technology
10.4.2.2.6. By Application
10.4.3. UAE Neoantigen Cancer Vaccine Market Outlook
10.4.3.1. Market Size & Forecast
10.4.3.1.1. By Value
10.4.3.2. Market Share & Forecast
10.4.3.2.1. By Product
10.4.3.2.2. By Neoantigen Type
10.4.3.2.3. By Route of Administration
10.4.3.2.4. By Cell
10.4.3.2.5. By Technology
10.4.3.2.6. By Application
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
13. Competitive Landscape
13.1. Competition Outlook
13.2. Players Profiled (Leading Companies)
13.2.1. OSE Immunotherapeutics SA
13.2.2. Gritstone bio, Inc.
13.2.3. BioNTech SE
13.2.4. F. Hoffmann-La Roche Ltd.
13.2.5. Pfizer Inc.
13.2.6. Merck & Co. Inc.
13.2.7. Moderna Inc.
13.2.8. Avidea Technologies, Inc.
13.2.9. Eli Lilly and Company
13.2.10. Vaccibody AS
13.2.11. Agenus Inc.
13.2.12. Novogene Co., Ltd.
13.2.13. ZIOPHARM Oncology Inc.
13.2.14. ISA Pharmaceuticals B.V.
13.2.15. BrightPath Biotherapeutics Co., Ltd.
13.2.16. Vaximm AG
13.2.17. Medigene AG
13.2.18. Genocea Biosciences Inc.
13.2.19. Advaxis, Inc.
13.2.20. Nouscom AG
14. Strategic Recommendations
15. About the Publisher & DisclaimerList of Figures
Figure 1: Global Neoantigen Cancer Vaccine Market Size, By Volume (Million Units), By Value (USD Million), 2020-2026F
Figure 2: Percentage Change in Healthcare Spending (2020-2021), By Region
Figure 3: Global Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 4: Global Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 5: Global Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 6: Global Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 7: Global Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 8: Global Neoantigen Cancer Vaccine Market Share, By Delivery Mechanism, By Value, 2020-2026F
Figure 9: Global Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 10: Global Neoantigen Cancer Vaccine Market Share, By Company, By Value, 2023
Figure 11: Global Neoantigen Cancer Vaccine Market Share, By Region, By Value, 2020 & 2026F
Figure 12: Global Neoantigen Cancer Vaccine Market Map, By Product, Market Size (USD Million) & Growth Rate (%)
Figure 13: Global Neoantigen Cancer Vaccine Market Map, By Neoantigen Type, Market Size (USD Million) & Growth Rate (%)
Figure 14: Global Neoantigen Cancer Vaccine Market Map, By Application, Market Size (USD Million) & Growth Rate (%)
Figure 15: Global Neoantigen Cancer Vaccine Market Map, By Region, Market Size (USD Million) & Growth Rate (%)
Figure 16: North America Neoantigen Cancer Vaccine Market Size, By Volume (Million Units), By Value (USD Million), 2020-2026F
Figure 17: North America Health Spending Share, By Value, 2020
Figure 18: North America Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 19: North America Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 20: North America Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 21: North America Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 22: North America Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 23: North America Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 24: North America Neoantigen Cancer Vaccine Market Share, By Country, By Value, 2020-2026F
Figure 25: North America Neoantigen Cancer Vaccine Market Map, By Product, Market Size (USD Million) & Growth Rate (%)
Figure 26: United States Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 27: New Cancer Cases Reported in the United States in 2020, Both Sexes, All Ages
Figure 28: United States Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 29: United States Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020 - 2026F
Figure 30: United States Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 31: United States Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 32: United States Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 33: United States Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 34: Canada Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 35: Canada Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 36: Canada Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 37: Canada Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 38: Canada Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 39: Canada Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 40: Canada Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 41: Mexico Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 42: Mexico Healthcare Spending, By Value, 2016 -2020 (USD Per Capita)
Figure 43: Mexico Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 44: Mexico Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 45: Mexico Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 46: Mexico Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 47: Mexico Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 48: Mexico Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 49: Europe Neoantigen Cancer Vaccine Market Size, By Volume (Million Units), By Value (USD Million), 2020-2026F
Figure 50: Leading Cancers in Europe, By Type, 2020
Figure 51: Europe Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 52: Europe Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 53: Europe Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 54: Europe Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 55: Europe Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 56: Europe Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 57: Europe Neoantigen Cancer Vaccine Market Share, By Country, By Value, 2020-2026F
Figure 58: Europe Neoantigen Cancer Vaccine Market Map, By Product, Market Size (USD Million) & Growth Rate (%)
Figure 59: Germany Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 60: Germany New Cancer Cases, By Type, 2020
Figure 61: Germany Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 62: Germany Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 63: Germany Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 64: Germany Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 65: Germany Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 66: Germany Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 67: France Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 68: France Total Population, (In Million), 2016-2020
Figure 69: France Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 70: France Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 71: France Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 72: France Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 73: France Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 74: France Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 75: United Kingdom Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 76: Geriatric Population Numbers & Projections in United Kingdom (Millions), 2020
Figure 77: United Kingdom Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 78: United Kingdom Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 79: United Kingdom Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 80: United Kingdom Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 81: United Kingdom Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 82: United Kingdom Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 83: Italy Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 84: New Cancer Cases in Italy (%), Males, All Ages, 2020
Figure 85: Italy Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 86: Italy Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 87: Italy Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 88: Italy Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 89: Italy Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 90: Italy Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 91: Spain Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 92: New Cancer Cases in Spain (%), Females, All Ages, 2020
Figure 93: Spain Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 94: Spain Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 95: Spain Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 96: Spain Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 97: Spain Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 98: Spain Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 99: Asia Pacific Neoantigen Cancer Vaccine Market Size, By Volume (Million Units), By Value (USD Million), 2020-2026F
Figure 100: Number of New Cancer Cases in Asia Pacific (2020)
Figure 101: Asia Pacific Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 102: Asia Pacific Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 103: Asia Pacific Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 104: Asia Pacific Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 105: Asia Pacific Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 106: Asia Pacific Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 107: Asia Pacific Neoantigen Cancer Vaccine Market Share, By Country, By Value, 2020-2026F
Figure 108: Asia Pacific Neoantigen Cancer Vaccine Market Map, By Product, Market Size (USD Million) & Growth Rate (%)
Figure 109: China Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 110: New Cancer Cases in China (%), 2020
Figure 111: China Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 112: China Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 113: China Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 114: China Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 115: China Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 116: China Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 117: India Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 118: Age Wise Prevalence of Breast Cancer in India, (%), Out of 100 Patients, 2020
Figure 119: India Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 120: India Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 121: India Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 122: India Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 123: India Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 124: India Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 125: Japan Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 126: Japan Total Health Expenditure as a share of GDP, 2016- 2020
Figure 127: Japan Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 128: Japan Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 129: Japan Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 130: Japan Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 131: Japan Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 132: Japan Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 133: Australia Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 134: % of Public and Private Hospitals in Australia, 2020
Figure 135: Australia Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 136: Australia Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 137: Australia Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 138: Australia Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 139: Australia Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 140: Australia Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 141: South Korea Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 142: New Cancer Cases in South Korea (%), 2020
Figure 143: South Korea Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 144: South Korea Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 145: South Korea Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 146: South Korea Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 147: South Korea Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 148: South Korea Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 149: Singapore Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 150: Singapore Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 151: Singapore Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 152: Singapore Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 153: Singapore Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 154: Singapore Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 155: Singapore Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 156: South America Neoantigen Cancer Vaccine Market Size, By Volume (Million Units), By Value (USD Million), 2020-2026F
Figure 157: South America New Cases of Cancer, By Type (%), 2020
Figure 158: South America Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 159: South America Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 160: South America Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 161: South America Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 162: South America Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 163: South America Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 164: South America Neoantigen Cancer Vaccine Market Share, By Country, By Value, 2020-2026F
Figure 165: South America Neoantigen Cancer Vaccine Market Map, By Product, Market Size (USD Million) & Growth Rate (%)
Figure 166: Brazil Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 167: Brazil Healthcare Spending, By Value (USD Per Capita), 2016-2020
Figure 168: Brazil Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 169: Brazil Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 170: Brazil Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 171: Brazil Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 172: Brazil Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 173: Brazil Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 174: Argentina Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 175: Argentina Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 176: Argentina Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 177: Argentina Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 178: Argentina Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 179: Argentina Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 180: Argentina Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 181: Colombia Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 182: New Cancer Cases in Colombia (%), 2020
Figure 183: Colombia Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 184: Colombia Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 185: Colombia Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 186: Colombia Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F:
Figure 187 Colombia Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 188: Colombia Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 189: Middle East and Africa Neoantigen Cancer Vaccine Market Size, By Volume (Million Units), By Value (USD Million), 2020-2026F
Figure 190: Middle East & Africa Geriatric Population Base (Age 60 & Above) % of Total Population, 2016-2020
Figure 191: Middle East & Africa Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 192: Middle East & Africa Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 193: Middle East & Africa Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 194: Middle East & Africa Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 195: Middle East & Africa Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 196: Middle East & Africa Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 197: Middle East and Africa Neoantigen Cancer Vaccine Market Share, By Country, By Value, 2020-2026F
Figure 198: Middle East and Africa Neoantigen Cancer Vaccine Market Map, By Product, Market Size (USD Million) & Growth Rate (%)
Figure 199: South Africa Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 200: South Africa New Cancer Cases, By Type, 2020
Figure 201: South Africa Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 202: South Africa Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 203: South Africa Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 204: South Africa Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 205: South Africa Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 206: South Africa Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 207: Saudi Arabia Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 208: Saudi Arabia New Cancer Cases, By Type, 2020
Figure 209: Saudi Arabia Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 210: Saudi Arabia Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 211: Saudi Arabia Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 212: Saudi Arabia Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 213: Saudi Arabia Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 214: Saudi Arabia Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 215: UAE Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
Figure 216: % of female population in UAE, 2016-2020
Figure 217: UAE Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
Figure 218: UAE Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
Figure 219: UAE Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
Figure 220: UAE Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
Figure 221: UAE Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
Figure 222: UAE Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
Figure 223: New Cancer Cases, By Type, 2020List of Tables
Table 1: Canada Cancer Statistics, As of 2020
Table 2: Singapore Cancer Statistics, As of 2020
Table 3: Argentina Cancer Statistics, As of 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- OSE Immunotherapeutics SA
- Gritstone bio, Inc
- BioNTech SE
- F Hoffmann-La Roche Ltd
- Pfizer Inc
- Merck & Co Inc
- Moderna Inc
- Avidea Technologies, Inc
- Eli Lilly and Company
- Vaccibody AS
- Agenus Inc
- Novogene Co, Ltd
- ZIOPHARM Oncology Inc
- ISA Pharmaceuticals BV
- BrightPath Biotherapeutics Co, Ltd
- Vaximm AG
- Medigene AG
- Genocea Biosciences Inc
- Advaxis, Inc
- Nouscom AG
